89 related articles for article (PubMed ID: 20821805)
1. Development of selected reaction monitoring-MS methodology to measure peptide biomarkers in prostate cancer.
Yocum AK; Khan AP; Zhao R; Chinnaiyan AM
Proteomics; 2010 Oct; 10(19):3506-14. PubMed ID: 20821805
[TBL] [Abstract][Full Text] [Related]
2. Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers.
Sardana G; Jung K; Stephan C; Diamandis EP
J Proteome Res; 2008 Aug; 7(8):3329-38. PubMed ID: 18578523
[TBL] [Abstract][Full Text] [Related]
3. [Markers for diagnosis, prediction and prognosis of prostate cancer].
Taskén KA; Angelsen A; Svindland A; Eide T; Berge V; Wahlquist R; Karlsen S
Tidsskr Nor Laegeforen; 2005 Dec; 125(23):3279-82. PubMed ID: 16327854
[TBL] [Abstract][Full Text] [Related]
4. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
6. A novel diagnostic test for prostate cancer emerges from the determination of alpha-methylacyl-coenzyme a racemase in prostatic secretions.
Zielie PJ; Mobley JA; Ebb RG; Jiang Z; Blute RD; Ho SM
J Urol; 2004 Sep; 172(3):1130-3. PubMed ID: 15311056
[TBL] [Abstract][Full Text] [Related]
7. Beyond PSA: utility of novel tumor markers in the setting of elevated PSA.
Lin DW
Urol Oncol; 2009; 27(3):315-21. PubMed ID: 19414121
[TBL] [Abstract][Full Text] [Related]
8. Tumor markers. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12-13, 1993.
Stamey TA; Ekman PE; Blankenstein MA; Cooper EH; Kontturi M; Lilja H; Oesterling JE; Stenman UH; Turkes A
Scand J Urol Nephrol Suppl; 1994; 162():73-87; discussion 115-27. PubMed ID: 7529430
[TBL] [Abstract][Full Text] [Related]
9. Elevated serum progastrin-releasing peptide (31-98) in metastatic and androgen-independent prostate cancer patients.
Yashi M; Muraishi O; Kobayashi Y; Tokue A; Nanjo H
Prostate; 2002 May; 51(2):84-97. PubMed ID: 11948963
[TBL] [Abstract][Full Text] [Related]
10. Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer.
Stephan C; Jung K; Lein M; Sinha P; Schnorr D; Loening SA
Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1133-47. PubMed ID: 11097220
[TBL] [Abstract][Full Text] [Related]
11. Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death.
Rubin MA; Bismar TA; Andrén O; Mucci L; Kim R; Shen R; Ghosh D; Wei JT; Chinnaiyan AM; Adami HO; Kantoff PW; Johansson JE
Cancer Epidemiol Biomarkers Prev; 2005 Jun; 14(6):1424-32. PubMed ID: 15941951
[TBL] [Abstract][Full Text] [Related]
12. Biomarkers for prostate cancer detection.
Reed AB; Parekh DJ
Expert Rev Anticancer Ther; 2010 Jan; 10(1):103-14. PubMed ID: 20014890
[TBL] [Abstract][Full Text] [Related]
13. Update on screening for prostate cancer with prostate-specific antigen.
Schmid HP; Riesen W; Prikler L
Crit Rev Oncol Hematol; 2004 Apr; 50(1):71-8. PubMed ID: 15094160
[TBL] [Abstract][Full Text] [Related]
14. The use of real-time reverse transcription-PCR for prostate-specific antigen mRNA to discriminate between blood samples from healthy volunteers and from patients with metastatic prostate cancer.
Patel K; Whelan PJ; Prescott S; Brownhill SC; Johnston CF; Selby PJ; Burchill SA
Clin Cancer Res; 2004 Nov; 10(22):7511-9. PubMed ID: 15569981
[TBL] [Abstract][Full Text] [Related]
15. [The search for better markers for prostate cancer than prostate-specific antigen].
Schenk-Braat EA; Bangma CH
Ned Tijdschr Geneeskd; 2006 Jun; 150(23):1286-90. PubMed ID: 16821452
[TBL] [Abstract][Full Text] [Related]
16. [Cancer of the prostate: advances in the use of PSA and its derived indices--new tumor markers].
Zlotta A; Schulman C
Rev Med Brux; 1999 Sep; 20(4):A201-5. PubMed ID: 10523893
[TBL] [Abstract][Full Text] [Related]
17. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
Mikolajczyk SD; Rittenhouse HG
Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
[TBL] [Abstract][Full Text] [Related]
18. Molecular markers of prostate cancer.
Bradford TJ; Tomlins SA; Wang X; Chinnaiyan AM
Urol Oncol; 2006; 24(6):538-51. PubMed ID: 17138135
[TBL] [Abstract][Full Text] [Related]
19. Discovery and clinical application of a novel prostate cancer marker: alpha-methylacyl CoA racemase (P504S).
Jiang Z; Woda BA; Wu CL; Yang XJ
Am J Clin Pathol; 2004 Aug; 122(2):275-89. PubMed ID: 15323145
[TBL] [Abstract][Full Text] [Related]
20. A sensitive proximity ligation assay for active PSA.
Zhu L; Koistinen H; Wu P; Närvänen A; Schallmeiner E; Fredriksson S; Landegren U; Stenman UH
Biol Chem; 2006 Jun; 387(6):769-72. PubMed ID: 16800738
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
